Genprex (NASDAQ:GNPX) Stock Price Down 3.2% – Should You Sell?

Genprex (NASDAQ:GNPX)’s stock price fell 3.2% during trading on Thursday . The stock traded as low as $0.28 and last traded at $0.28. 999,156 shares traded hands during trading, a decline of 76% from the average session volume of 4,190,090 shares. The stock had previously closed at $0.29.

Genprex Stock Performance

The firm’s 50 day moving average is $0.28 and its 200 day moving average is $0.39.

Genprex (NASDAQ:GNPX) last issued its earnings results on Monday, May 12th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.82) by $0.56. On average, analysts expect that Genprex will post -5.7 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Genprex stock. Geode Capital Management LLC raised its holdings in shares of Genprex (NASDAQ:GNPX) by 368.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 76,045 shares of the company’s stock after buying an additional 59,798 shares during the period. Geode Capital Management LLC owned about 0.89% of Genprex worth $65,000 at the end of the most recent quarter. 14.05% of the stock is owned by hedge funds and other institutional investors.

About Genprex

Genprex, Inc, a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes.